Express Scripts calls Gilead action 'step in the right direction'
Express Scripts (ESRX) says in a statement on its website, "Our reimbursement system for medications is complex, but our intentions are clear: we want to ensure affordable access for patients and payers. In our response to the Administration's Drug Pricing Blueprint, we suggested a pathway for drug makers to introduce lower list prices for products that currently have high list prices and high rebates in way that will not destabilize the drug supply chain, while giving cash-paying patients immediate access to more affordable medicine. Today's action by Gilead Sciences is a step in the right direction, and we are encouraged that a drug maker is finally taking meaningful action to bring prices down for cash-paying customers." The statement is titled "We Offered a Path to Lower Drug Prices And Gilead Listened." Reference Link ESRX GILD